Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone353-1485-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$103.27 million
Profitability
Miscellaneous
Employees144
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions
What is Avadel Pharmaceuticals' stock symbol?
Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How will Avadel Pharmaceuticals' stock buyback program work?
Avadel Pharmaceuticals declared that its board has authorized a stock repurchase program on Wednesday, March 28th 2018, which allows the company to buyback $7,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board believes its shares are undervalued.
How were Avadel Pharmaceuticals' earnings last quarter?
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings data on Friday, August, 9th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $17.55 million for the quarter. Avadel Pharmaceuticals had a negative net margin of 135.48% and a negative return on equity of 608.04%. View Avadel Pharmaceuticals' Earnings History.
When is Avadel Pharmaceuticals' next earnings date?
What price target have analysts set for AVDL?
2 brokerages have issued 1 year price targets for Avadel Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they anticipate Avadel Pharmaceuticals' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.
What is the consensus analysts' recommendation for Avadel Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avadel Pharmaceuticals.
Has Avadel Pharmaceuticals been receiving favorable news coverage?
Media coverage about AVDL stock has been trending somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Avadel Pharmaceuticals.
Who are some of Avadel Pharmaceuticals' key competitors?
Some companies that are related to Avadel Pharmaceuticals include BIOFRONTERA AG/ADR (BFRA), Minerva Neurosciences (NERV), Avid Bioservices (CDMO), CV Sciences (CVSI), Clovis Oncology (CLVS), OvaScience (OVAS), Geron (GERN), Assembly Biosciences (ASMB), NuCana (NCNA), Dynavax Technologies (DVAX), Urovant Sciences (UROV), Xeris Pharmaceuticals (XERS), OptiNose (OPTN), Kalvista Pharmaceuticals (KALV) and Rigel Pharmaceuticals (RIGL).
What other stocks do shareholders of Avadel Pharmaceuticals own?
Who are Avadel Pharmaceuticals' key executives?
Avadel Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
- Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
- Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)
- Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52)
Who are Avadel Pharmaceuticals' major shareholders?
Avadel Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (18.17%), Brown Capital Management LLC (4.08%), Renaissance Technologies LLC (2.15%), Morgan Stanley (1.92%), Acadian Asset Management LLC (0.57%) and CIBC Private Wealth Group LLC (0.40%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, James E Flynn, Michael S Anderson, Peter J Thornton and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.
Which institutional investors are selling Avadel Pharmaceuticals stock?
Which institutional investors are buying Avadel Pharmaceuticals stock?
AVDL stock was bought by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Renaissance Technologies LLC, Brown Capital Management LLC, Susquehanna International Group LLP, JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Michael S Anderson and Peter J Thornton. View Insider Buying and Selling for Avadel Pharmaceuticals.
How do I buy shares of Avadel Pharmaceuticals?
Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avadel Pharmaceuticals' stock price today?
One share of AVDL stock can currently be purchased for approximately $2.46.
How big of a company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals has a market capitalization of $91.89 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe.View Additional Information About Avadel Pharmaceuticals.
What is Avadel Pharmaceuticals' official website?
How can I contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 353-1485-1200 or via email at [email protected]
MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
